|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer
|
Michael Williams, MD, MS, and Mark Fleming, MD
Michael Williams and Mark Fleming discuss their collaborative approach to managing patients with metastatic prostate cancer. Drs. Williams and Fleming emphasize the importance of multidisciplinary care, sharing a case of a patient with high-volume disease treated with an oral LHRH antagonist and enzalutamide.
|
|
|
|
|
|
|
|
|
|
|
|
Building an Integrated, Multidisciplinary Team to Optimize Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer
|
Chandler Park, MD, and Ryan Malone, MD
Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases.
|
|
|
|
|
|
|
|
|
|
|
| Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC |
Tanya Dorff, MD
Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone mCRPC. The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. |
|
|
|
|
|
|
|
|
|
|
| Low- and High-Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study |
| Lena Unterrainer, MD |
| Lena Unterrainer presented a study comparing low- and high-volume disease definitions in mHSPC using conventional imaging (CT + bone scan) and PSMA-PET. Results showed a discrepancy in volume classifications between the two imaging modalities, with 40.3% of patients experiencing an upshift or downshift in volume status when transitioning from conventional imaging to PSMA-PET. |
|
|
|
|
|
| Metastatic Hormone-Sensitive Prostate Cancer: Impact of Disease Volume and Timing of Metastases |
| Rashid Sayyid, MD, MSc, and Zachary Klaassen, MD, MSc |
| Rashid Sayyid and Zachary Klaassen discuss the evolution of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) since 2015, emphasizing the impact of doublet and triplet therapies using ADT as the backbone. The pair highlight the significance of distinguishing between de novo and metachronous mHSPC, as well as the stratification by volume of metastatic disease, with specific attention to the CHAARTED criteria. |
|
|
|
|
|
|
|
|
|
|
| Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams - Beyond the Abstract
|
| Neal D. Shore, MD, FACS, Alicia Morgans, MD, MPH, Ghassan El-Haddad, MD, Sandy Srinivas, MD, and Matthew Abramowitz, MD, MS
|
| Neal Shore et al. emphasize the importance of multidisciplinary teams in prostate cancer management, particularly in light of rapidly evolving diagnostic and treatment options. They highlight how MDTs can integrate new diagnostic technologies, address emerging challenges, and overcome disparities in care, and call for further research to fill existing gaps in evaluating MDT success and payment models.
|
|
|
|
|
|
| Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
|
| Marybeth Nedrud, MD, Ph.D.
|
| Marybeth Nedrud presents outcomes of implementing a multidisciplinary approach for Lu177-PSMA-617 (LuPSMA) therapy at Duke University, where successful treatment coordination involves nuclear medicine, radiation safety, and medical oncology. Among 98 patients receiving LuPSMA, the median number of treatments was 4.0, with 41% completing all 6 planned treatments. Treatment holds and dose reductions were utilized in some cases to facilitate completion, and early discontinuation was primarily due to disease progression.
|
|
|
|
|
|
| Multidisciplinary Management from Medical Oncology
|
| Rana McKay, MD
|
| Rana McKay discusses the multidisciplinary management of RCC from the medical oncology perspective. Dr. McKay highlights the potential role of SABR across various disease stages, including localized, oligometastatic, and oligoprogressive disease. Dr. McKay also reviewed ongoing trials investigating the combination of SABR with immunotherapy in the oligometastatic setting and emphasized the importance of novel imaging modalities for disease detection and response assessment.
|
|
|
|
|
|
|
|
|
|
|
|
